Strong Financial Performance
ODDITY reported a 24% revenue growth and 24% growth in adjusted diluted earnings per share year-over-year, exceeding targets and raising full year guidance.
Successful Launch of METHODIQ
METHODIQ, ODDITY's third brand, launched successfully with a focus on dermatology and plans to expand into new medical domains. It includes a line of 28 prescription and nonprescription products.
International Expansion
International revenue increased by around 40% year-over-year in the first 9 months of 2025, with successful scaling in markets like the U.K. and Australia.
Growth in IL MAKIAGE and SpoiledChild
IL MAKIAGE achieved double-digit online growth and is on track for $1 billion revenue by 2028. SpoiledChild expected to cross $225 million in revenue in 2025.
ODDITY LABS Progress
ODDITY LABS plans to have at least 8 products with proprietary molecules on the market in 2026, contributing to strong commercial discoveries.